Market Overview

MannKind Corporation Posts In-Line Q4; Expense Falls 35%

Share:
Related MNKD
MannKind, Sanofi Reach Agreement on AFREZZA; Sanofi to Purchase $10.2M Worth of Insulin from MannKind
Earnings Scheduled For November 9, 2016
MannKind: Afrezza Sales Start Off 2017 Modestly. Will A Bigger Sales Force Make A Material Difference? (Seeking Alpha)

MannKind Corp. (NASDAQ: MNKD) gained in Tuesday's extended session after the drug company posted a fourth-quarter loss in line with expectations and said operating expense fell 35 percent.

Shares of the Valencia, California development-stage company changed hands recently at $7, up more than 4 percent.

Mannkind posted a net loss of $36.4 million, or $0.09 a share, versus a year-earlier net loss of 53.6 million, or $0.16 a share.

Wall Street expected a loss of $0.09 a share.

Although revenue was negligible, the company noted that it launched its Afrezza inhalable insulin in the fourth quarter, and said operating expenses declined 35 percent from a year earlier on lower research and development costs.

General and administrative costs declined 29 percent, mainly on lower non-cash compensation expenses.

Posted-In: Earnings News Guidance After-Hours Center

 

Related Articles (MNKD)

View Comments and Join the Discussion!